Adaptimmune Therapeutics Stock (NASDAQ: ADAP) stock price, news, charts, stock research, profile.
Open | $1.20 |
Close | - |
Volume / Avg. | 1.49M / 1.58M |
Day Range | 1.15 - 1.23 |
52 Wk Range | 0.42 - 2.05 |
Market Cap | $304.17M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 62 |
Short Interest | 2.88% |
Days to Cover | 3.02 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Adaptimmune Therapeutics (NASDAQ:ADAP) through any online brokerage.
Other companies in Adaptimmune Therapeutics’s space includes: Macrogenics (NASDAQ:MGNX), Zentalis Pharma (NASDAQ:ZNTL), Inozyme Pharma (NASDAQ:INZY), Fate Therapeutics (NASDAQ:FATE) and Kyverna Therapeutics (NASDAQ:KYTX).
There is no analysis for Adaptimmune Therapeutics.
Adaptimmune Therapeutics has a consensus price target of $4.56.
The stock price for Adaptimmune Therapeutics (NASDAQ: ADAP) is $1.1902 last updated Today at July 9, 2024 at 3:43 PM EDT.
There are no upcoming dividends for Adaptimmune Therapeutics.
Adaptimmune Therapeutics’s Q2 earnings are confirmed for Wednesday, August 7, 2024.
There is no upcoming split for Adaptimmune Therapeutics.
Adaptimmune Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.